Advancing your cell therapy development workflow
Cell therapy is one of the most exciting and dynamic fields in modern medicine. Thermo Fisher Scientific believes in the promise of cell therapies to cure what was once thought of as incurable. We know this begins with careful material selection from process development through to clinical trials and commercial manufacturing.
In this article series, we will focus on innovations in isolation, activation, and expansion of T cells to help you further your progress and support your journey to success.
In a landscape of rapid market growth with a high pace of innovation, you need to keep up to realize your therapy’s full potential. Speed is therefore one of the most pressing challenges for cell therapy development and manufacturing. Discover how to streamline your workflow across cell isolation, activation, and expansion to stay ahead and help accelerate your treatments to patients.
Watch this animated video of a cell therapy workflow. See how Thermo Fisher Scientific’s cell therapy products have been designed to work together to decrease manufacturing time and maintain the cell phenotype while being scalable to meet the needs of autologous and allogeneic therapies for clinical and commercial manufacturing.
Gibco™ CTS™ Detachable Dynabeads™ CD3/CD28 and Gibco™ CTS™ Detachable Dynabeads™ Release Buffer build on the one-step isolation/activation feature of CTS™ Dynabeads™ CD3/CD28 by adding an active release mechanism. Together they help preserve an early T cell phenotype and shorten the T cell manufacturing process to a few days.
See how CTS Detachable Dynabeads work.
A robust cell culture medium is vital for consistent T cell expansion when scaling up to automated stirred-tank bioreactors for cell therapy production.
A medium is evaluated with cells from healthy donors, as well as cells from diseased donors from two clinical indications, acute myeloid leukemia (AML) and CLL.
